In 1972, topical tretinoin (Retin-A, Ortho Pharmaceutical) wasapproved for the treatment of acne. Today this remains the onlymedical indication for its use approved by the Food and DrugAdministration (FDA). In 1988 a highly publicized study reportedthat topical tretinoin improves the appearance of "photoaged"skin1. Since then, the manufacturer of topical tretinoin hasconducted an active, controversial multimedia effort to ensurethat the general public and the medical profession are awareof the "unlabeled" use of tretinoin to treat benign cutaneouschanges, such as wrinkles and brown spots, that may be annoyingto patients because of . . . [Full Text of this Article]
Methods
Results
Discussion
Source Information
From the Department of Dermatology, Beth Israel Hospital, and Harvard Medical School, Boston.
Address reprint requests to Dr. Stern at Beth Israel Hospital, 330 Brookline Ave., Boston, MA 02215.
References
Related Letters:
Drug Promotion
Hoberman D., Puma J. L., Cohen S. N., Mossinghoff G. J., Stryer D. B., Bero L. A., Kalish R. S., Kessler D. A., Rose J. L., Temple R. J., Schapiro R., Griffin J. P., Stern R. S.
Extract |
Full Text
N Engl J Med 1995;
332:1031-1033, Apr 13, 1995.
Correspondence
This article has been cited by other articles:
Atherly, A., Rubin, P. H.
(2009). The Cost-Effectiveness of Direct-to-Consumer Advertising for Prescription Drugs. Med Care Res Rev
66: 639-657
[Abstract]
Cohen, J. S., Insel, P. A.
(1996). The Physicians' Desk Reference: Problems and Possible Improvements. Arch Intern Med
156: 1375-1380
[Abstract]
Vermeer, B. J., Gilchrest, B. A., Vermeer, , Friedel, S. L.
(1996). Cosmeceuticals: A Proposal for Rational Definition, Evaluation, and Regulation. Arch Dermatol
132: 337-340
[Abstract]
Hoberman, D., Puma, J. L., Cohen, S. N., Mossinghoff, G. J., Stryer, D. B., Bero, L. A., Kalish, R. S., Kessler, D. A., Rose, J. L., Temple, R. J., Schapiro, R., Griffin, J. P., Stern, R. S.
(1995). Drug Promotion. NEJM
332: 1031-1033
[Full Text]